Dihydrotanshinone I是丹参中主要的一种脂溶性phenanthioquinone化合物，具有抗肿瘤特性。
Cas No.:87205-99-0
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Dihydrotanshinone I is the principal lipophilic phenanthioquinone compound found in Salvia miltiorrhiza Bunge, with antitumor properties [1]. Dihydrotanshinone I mainly induced intrinsic apoptosis mediated by regulation of Bcl-2 family proteins and activation of caspases, which included decreasing mitochondria membrane potential, inhibiting expression of anti-apoptotic protein such as Bcl-xL, Bcl-2[2]. Dihydrotanshinone I has been widely used to inhibit the growth of Gram-positive bacteria and to suppress the expression of pro-inflammatory genes[3].
In vitro, Dihydrotanshinone I significantly inhibited the proliferation of U-2 OS cells, HeLa cells, and NRK-49F cells after 24 hours of treatment, with IC50 values of 3.83μM, 15.48μM, and 25.00μM, respectively[4]. Treatment with 20μM Dihydrotanshinone I for 24 hours significantly induced apoptosis in HCT116 cells, accompanied by an increase in caspase-3/9 levels and the degradation of p62[5]. Treatment of MDA-MB-468 cells with 1μM Dihydrotanshinone I for 24 hours resulted in decreased expression of mesenchymal markers (such as vimentin, N-cadherin and active β-catenin), and inhibition of colony formation[6].
In vivo, Dihydrotanshinone I treatment via oral administration at a dose of 25mg/kg/day for three consecutive days alleviated the pathological changes of colitis in mice induced by dextran sulfate sodium salt (DSS), and inhibited the secretion of inflammatory cytokines[7]. Intraperitoneal injection of Dihydrotanshinone I (10mg/kg) was administered three times a week for 4 weeks, which inhibited the tumor growth in the MDA-MB-231 cell-xenograft mouse model[8].
References:
[1] Yue J, Hao D, Wang Y, et al. The multifaceted mechanisms of Dihydrotanshinone I in the treatment of tumors[J]. Biomedicine & Pharmacotherapy, 2024, 175: 116635.
[2] Chen X, Yu J, Zhong B, et al. Pharmacological activities of dihydrotanshinone I, a natural product from Salvia miltiorrhiza Bunge[J]. Pharmacological Research, 2019, 145: 104254.
[3] Jiang Z, Gao W, Huang L. Tanshinones, critical pharmacological components in Salvia miltiorrhiza[J]. Frontiers in Pharmacology, 2019, 10: 202.
[4] Fan L, Peng C, Zhu X, et al. Dihydrotanshinone I Enhances Cell Adhesion and Inhibits Cell Migration in Osteosarcoma U− 2 OS Cells through CD44 and Chemokine Signaling[J]. Molecules, 2022, 27(12): 3714.
[5] Wang L, Hu T, Shen J, et al. Dihydrotanshinone I induced apoptosis and autophagy through caspase dependent pathway in colon cancer[J]. Phytomedicine, 2015, 22(12): 1079-1087.
[6] Kashyap A, Umar S M, JR A D, et al. Dihydrotanshinone-I modulates epithelial mesenchymal transition (EMT) thereby impairing migration and clonogenicity of triple negative breast cancer cells[J]. Asian Pacific Journal of Cancer Prevention: APJCP, 2021, 22(7): 2177.
[7] Guo Y, Wu X, Wu Q, et al. Dihydrotanshinone I, a natural product, ameliorates DSS-induced experimental ulcerative colitis in mice[J]. Toxicology and applied pharmacology, 2018, 344: 35-45.
[8] Tsai S L, Suk F M, Wang C I, et al. Anti-tumor potential of 15, 16-dihydrotanshinone I against breast adenocarcinoma through inducing G1 arrest and apoptosis[J]. Biochemical pharmacology, 2007, 74(11): 1575-1586.
Dihydrotanshinone I是丹参中主要的一种脂溶性phenanthioquinone化合物，具有抗肿瘤特性[1]。Dihydrotanshinone I主要通过调控Bcl-2家族蛋白和激活caspase诱导内在凋亡途径，包括降低线粒体膜电位、抑制抗凋亡蛋白如Bcl-xL、Bcl-2的表达[2]。Dihydrotanshinone I已被广泛用于抑制革兰氏阳性菌的生长以及抑制促炎基因的表达[3]。
在体外，Dihydrotanshinone I处理24小时显著抑制了U-2 OS细胞、HeLa细胞和NRK-49F细胞的增殖，IC50值分别为3.83µM、15.48µM和25.00µM[4]。使用20µM的Dihydrotanshinone I处理24小时，显著诱导了HCT116细胞凋亡，并伴有caspase-3/9水平的升高和p62的降解[5]。用1µM的Dihydrotanshinone I处理MDA-MB-468细胞24小时，导致间充质标志物（如波形蛋白、N-钙黏蛋白和活性β-连环蛋白）表达下降，并抑制了克隆形成[4]。
在体内，每日口服给予25mg/kg剂量的Dihydrotanshinone I，连续三天，减轻了葡聚糖硫酸钠盐（DSS）诱导的小鼠结肠炎病理变化，并抑制了炎症细胞因子的分泌[7]。每周三次腹腔注射Dihydrotanshinone I（10mg/kg），持续四周，抑制了MDA-MB-231细胞异种移植小鼠模型中的肿瘤生长[8]。
| Cell experiment [1]: | |
Cell lines | HCT116 cells |
Preparation Method | HCT116 cells were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS), 100mg/l penicillin G and 100U/ml streptomycin, under conditions of 37℃ and 5% CO2. The cells were inoculated into 24-well plates and cultured at 37℃ overnight. Cells were treated with different concentrations of Dihydrotanshinone I (0.325, 6.25, 12,5, and 20µM) for 24 hours. The 0.1% (v/v) DMSO solution was used as the solvent control group. After 24 hours, the apoptosis of the cells was detected. |
Reaction Conditions | 0.325, 6.25, 12,5, and 20µM; 24h |
Applications | Dihydrotanshinone I treatment induced apoptosis in HCT116 cells in a dose-dependent manner. |
| Animal experiment [2]: | |
Animal models | Male Balb/cAnN-Foxn1 nude mice |
Preparation Method | Male Balb/cAnN-Foxn1 nude mice (4-5 weeks old) were housed in a standard animal room for 1-2 weeks before the experiment. Each group consisted of 5 mice, and 5×106 MDA-MB-231 cells were subcutaneously injected between the scapulae of each mouse. One week after transplantation, the mice were intraperitoneally injected with 40μl DMSO (control group) or 10mg/kg Dihydrotanshinone I three times a week for 4 weeks. At the end of the experiment, the mice were euthanized by cervical dislocation, and tumor specimens were collected, photographed, and weighed. |
Dosage form | 10mg/kg; three times a week for 4 weeks; i.p. |
Applications | Dihydrotanshinone I treatment reduced the tumor growth in MDA-MB-231 cell-xenograft mouse models. |
References: | |
| Cas No. | 87205-99-0 | SDF | |
| 别名 | 二氢丹参酮 I | ||
| 化学名 | (1R)-1,6-dimethyl-1,2-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione | ||
| Canonical SMILES | CC1COC2=C1C(=O)C(=O)C3=C2C=CC4=C3C=CC=C4C | ||
| 分子式 | C18H14O3 | 分子量 | 278.3 |
| 溶解度 | DMF: 0.2 mg/ml,DMSO: 0.2 mg/ml | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.5932 mL | 17.9662 mL | 35.9324 mL |
| 5 mM | 718.6 μL | 3.5932 mL | 7.1865 mL |
| 10 mM | 359.3 μL | 1.7966 mL | 3.5932 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet